Scarica l'app Stockscreener
4.41
2.80%
0.12
Dopo l'orario di chiusura:
4.41
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Capitals Announce ALL CAPS 2025 Playoffs Initiatives Presented by Vanda Pharmaceuticals Inc. - NHL.com
FDA Drug Rules Under Fire in Pharma Free Speech Fight - Law360
Vanda Sues FDA To Block Off-Label Use Drug Promo Regs - Law360
Vanda Pharmaceuticals: Financials Are Great, But Market Reaction Is Confusing (VNDA) - Seeking Alpha
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting - Nasdaq
FDA-Designated Precision Medicine Breakthrough: New Hope for Rare Genetic Disease Patients - Stock Titan
Class Action Update Vanda Pharmaceuticals Inc. (VNDA) & Stamps.com Inc. (STMP)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
Class Action Update Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
Class Action Notice Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
High Growth Tech Stocks In US With Promising Potential - simplywall.st
Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals - Benzinga
Vanda Pharmaceuticals Seeks US FDA Approval for Bysanti to Treat Schizophrenia, Acute Bipolar I Disorder - MarketScreener
Vanda Pharmaceuticals submits NDA to FDA for Bysanti - TipRanks
Vanda seeks FDA nod for new bipolar, schizophrenia drug - Investing.com
Vanda seeks FDA nod for new bipolar, schizophrenia drug By Investing.com - Investing.com UK
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - PR Newswire
HC Wainwright maintains $20 target on Vanda Pharmaceuticals stock By Investing.com - Investing.com UK
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate - MarketScreener
Vanda Pharmaceuticals announces FDA review date for new drug By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals announces FDA review date for new drug - Investing.com
Vanda Pharmaceuticals’ New Drug Application Accepted by FDA - TipRanks
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - GuruFocus.com
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus.com
Insider Buying: Mihael Polymeropoulos Acquires 10,000 Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus.com
CLASS ACTION UPDATE for VNDA, CTL and INGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
CLASS ACTION UPDATE for AVEO, KHC and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires $50,200.00 in Stock - MarketBeat
Vanda Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Vanda Pharmaceuticals CEO Mihael Polymeropoulos buys $50,150 in stock By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals CEO Mihael Polymeropoulos buys $50,150 in stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $50,150 worth of shares (10,000 units at $5.01), increasing direct ownership by 0.44% to 2,295,731 units (SEC Form 4) - Quantisnow
CLASS ACTION UPDATE for AVEO, DPLO and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Vanda Pharmaceuticals CEO Mihael Polymeropoulos acquires $50,200 in stock By Investing.com - Investing.com India
US FDA Spikes Vanda’s Hetlioz For Insomnia, Lack Of Well-Controlled Trial ‘Fatal’ - Citeline News & Insights
Vanda Pharmaceuticals CEO Mihael Polymeropoulos acquires $50,200 in stock - Investing.com
President and CEO Polymeropoulos Mihael Hristos bought $50,200 worth of shares (10,000 units at $5.02), increasing direct ownership by 0.44% to 2,285,731 units (SEC Form 4) - Quantisnow
President and CEO Polymeropoulos Mihael Hristos covered exercise/tax liability with 95,999 shares and bought $47,050 worth of shares (10,000 units at $4.71), decreasing direct ownership by 4% to 2,275,731 units (SEC Form 4) - Quantisnow
CLASS ACTION UPDATE for TYME, GE and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Allspring Global Investments Holdings LLC Sells 77,738 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos Purchases 10,000 Shares - MarketBeat
Vanda Pharmaceuticals CEO acquires $47,600 in common stock By Investing.com - Investing.com Australia
Vanda Pharmaceuticals CEO acquires $47,600 in common stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $47,600 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,361,730 units (SEC Form 4) - Quantisnow
US High Growth Tech Stocks With Strong Potential - Yahoo Finance UK
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
February 2025 Penny Stocks To Keep An Eye On - Simply Wall St
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):